To compare the time spent in specified glycaemic ranges in people with type 1 diabetes (T1D) during 5 consecutive days of moderate-intensity exercise while on either 100% or 75% of their usual insulin degludec (IDeg) dose.
and IGlar, despite different pharmacodynamic profiles and duration of action. 4 Various therapy strategies have been suggested to reduce the risk of exercise-induced hypoglycaemia, namely, prandial bolus insulin dose reductions, additional carbohydrate consumption and/or basal insulin reductions. 5 Therapy adjustment is mainly based on acute exercise-specific factors, such as the intensity, duration and type of exercise; however, other factors, such as circulating insulin concentrations, hepatic and skeletal muscle glycogen storage and counterregulatory hormone concentrations need to be considered when performing exercise. Patients on multiple daily injections are advised to reduce pre-and post-exercise prandial bolus insulin dose by 25%
for low-intensity, 50% for moderate-intensity and 75% for highintensity exercise performed for 30 to 45 minutes. 6 Blood glucose levels between 7 mmol/L (126 mg/dL) and 10 mmol/L (180 mg/dL) should be targeted by administering additional carbohydrates depending on the volume of exercise (eg, 15-20 g/h). 6 An unaltered usual dose of IDeg can be employed safely as a background insulin if patients wish to engage in low-, moderate-and high-intensity exercise when applying bolus insulin dose reductions. 7, 8 The risk of hypoglycaemia of an acute bout of exercise may persist for at least 24 hours, driven partly by circulating insulin levels and increased tissue insulin sensitivity. 5 Although basal rate reductions are recommended in patients running on continuous subcutaneous insulin infusion, limited data exist on basal insulin dose reductions for multiple dose insulin injections. 5, 9 Campbell et al 10 reported that reducing the basal insulin dose combined with reduced prandial bolus insulin dose protects the individual from hypoglycaemia for 24 hours after moderate-intensity exercise. Importantly, these adjustments were not associated with significant increases in time spent in hyperglycaemia (67 AE 16 minutes) or hypoglycaemia (5 AE 6 minutes) within the 24 hours post-exercise period.
The vast majority of research investigating the safety of basal insulins assessed only an acute bout of exercise. 4, 8, 11 In line with international guidelines, individuals with type 1 diabetes (T1D) are recommended to exercise regularly as part of their usual care. 9 This raises the question of whether regular exercise exposes the patient to a greater risk of hypoglycaemia as a result of the additive insulinsensitizing effects of these repeated exercise bouts.
Regular exercise is a cornerstone of good diabetes management and more people with T1D are channelling their motivation to exercise into attempting sport events such as marathon running, long distance cycling or triathlons. 12, 13 This commitment is accompanied by regular training for many months, with acute exercise sessions often performed over consecutive days. The same is also true for people with T1D performing a week of irregular exercise, such as a skiing week or an activity holiday. 14 Considering the long-lasting effect of IDeg, [1] [2] [3] rapid changes in the circulating IDeg concentrations for isolated exercise bouts are not possible; however, there is no research in the literature that has explored the impact of IDeg dose reduction on glycaemia when people with T1D are regularly exercising. Interestingly, despite this lack of research, a recent review did not recommend
IDeg dose reductions around regular exercise because this might compromise overall glycaemic control. 5 Nocturnal hypoglycaemia, a potentially life-threatening event, 15, 16 occurs more frequently in people with T1D after performing exercise compared with when daily exercise was not performed because of the extended effect of exercise. 17 The incidence of developing post-exercise hypoglycaemia after moderate-intensity exercise has been reported to be up to 66% in individuals with T1D across studies. 18, 19 So far, no research has investigated the effect of basal insulin dose reductions on day-and nighttime glycaemia when patients are exercising regularly.
In the present study, we compared the time spent in specified glycaemic ranges during 5 consecutive days of continuous moderateintensity exercise, stratified for time of day as well as for first and last period within the 5 days, either treated with 100% or 75% of their usual IDeg dose in people with T1D. LTP 2 ) as well as the maximum power output (P max ) were determined to prescribe the exercise intensity for the upcoming two exercise periods. [20] [21] [22] As participants were already on IDeg (Tresiba; Novo Additionally, participants changed the sensor earlier if the sensor would expire within the 5-day exercise period. Data were then exported at the end of each dosing scheme and 15-minute averaged data were used for the analyses. Seven participants were already using the intermittently viewed CGM system prior to the start of the study.
| MATERIAL AND METHODS

| Study procedures
| Trial visits
Three days before the first exercise period, participants were randomized to either 100% or 75% of their usual IDeg dose, injected oncedaily in the evening. Randomization was performed using the web- 
| Statistical analyses
The sample size was estimated using the calculator freely available at http://www.sample-size.net, applying a paired Student's t test. For the sample size estimation, we assumed a mean time in euglycaemia in the full basal insulin dosing scheme (100% IDeg) of 643 AE 54 min/d. 
| RESULTS
Out of 11 patients screened, 10 were eligible and randomized in the study. Nine participants completed both trial arms as one patient withdrew after the first exercise period for personal reasons. Data for this participant were not used in the analysis. All included participants were already on IDeg at least 3 months prior to the start of the study. carbohydrate amount at their last pre-exercise meals was also comparable between the dosing schemes (100% IDeg 62 AE 6 g vs. 75% IDeg 64 AE 15 g, respectively; P = 0.83). Absolute recorded time periods with available glucose readings were similar in both dosing schemes (P = 0.15), hence we used calculations for absolute and relative time spent in glycaemic ranges for our analyses.
| Participant characteristics
The four women and five men completing the present study had a mean AE SD age of 32.1 AE 9.0 years, a mean AE SD body mass index of 25. 
| Physiological and performance data
The 100% IDeg dose corresponded to a mean AE SD total daily basal insulin dose of 19 AE 4 IU while for 75% IDeg it was 14 AE 3 IU. The mean physiological characteristics over the 5 exercising days were similar during the 100% IDeg and 75% IDeg dosing periods (Table 1 ).
| Glycaemic responses during the 5-day exercise period
Glycaemic data were compared from immediately post-first exercise session until 24 hours post-last exercise session for each dosing period. The 75% IDeg dose resulted in a significant increase in time spent in euglycaemia (P = 0.04). No significant differences were found for time spent in hypo-and hyperglycaemic ranges, hypoglycaemic episodes, glycaemic variation, carbohydrate consumption or insulin administration, as shown in Table 2 (P > 0.05).
| Glycaemia at daytime versus night-time during the 5-day exercise period
While there was a numerical trend for more time spent in euglycaemia for the 75% IDeg dosing period during night-time, it did not reach statistical significance (P = 0.059; Table 3 ):
3.5 | Glycaemia during the first and last phase of the exercise period No significant differences for glycaemic ranges were found comparing the 100% IDeg and 75% IDeg period when analysing data within the first 48 hours and last 48 hours of the 5-day exercise intervention (P > 0.05; Table 4 ). 
| Plasma insulin levels
No significant differences were found for plasma insulin concentrations in the two dosing schemes (P = 0.34). Significant differences were found within dosing schemes in plasma insulin levels over the time course (basal insulin dose × time) with a drop during the exercise and a rise over the next 23 hours (P = 0.002; Figure 1 ). Although participants administered similar amounts of prandial insulin for both dosing schemes, the prandial carbohydrate intake was non-significantly but numerically higher for the 75% IDeg dosing scheme while the correction carbohydrate intake was numerically higher during the 100% IDeg dosing scheme. It could be speculated that participants were more hesitant about having additional correction carbohydrates as they knew they were on the lower basal insulin dose; however, given these inconclusive data, the small proportion of time spent in hypoglycaemia and the fact that none of these findings were statistically significant, future, larger studies are needed to clarify the impact of various IDeg doses on hypoglycaemia.
Importantly, the reductions in IDeg dose did not alter bolus insulin therapy while improving time spent in euglycaemia, which support the ease of use in regularly exercising people with T1D. A non-significant difference was observed for heart rate (−3 AE 0.4 b/min) and RER (−0.01 AE 0.03) when comparing the two dosing schemes, which was considered biological variability.
The effects of regular exercise training on glycaemic control are equivocal. 25 Exercise may lead to a glycaemic benefit in young people with T1D when undertaken for longer periods, but this was not found in adults with T1D. A potential reason for this finding may be a mandatory increased carbohydrate intake to prevent exercise-induced hypoglycaemia leading to a mismatch of carbohydrate to insulin ratio.
Reducing the basal insulin dose by 25% might support the beneficial effects of regular exercise on glycaemic control in individuals with T1D if additional carbohydrate intake is reduced.
Regular exercise increases insulin sensitivity in both people with type 1 and those with type 2 diabetes. 26, 27 The physiological underpinning mainly lies in the transcription of glucose transport proteins (glucose transporter type 4), its movement and insertion into membranes, facilitating insulin-independent intramuscular glucose uptake. 28 While blood glucose homeostasis in healthy individuals is regulated via increasing counterregulatory hormones and its effect on hepatic glycogen depletion, glucagon fails to increase in people with IDeg. As participants were trained in how to prevent nocturnal hypoglycaemia, this potentially had an influence on our results. Training was needed for safety reasons as participants used an intermittently viewed CGM system instead of real-time CGM, which does not offer an automatic hypoglycaemia alarm.
The coefficient of variation in glycaemia was similar when comparing dosing schemes for the 5-day exercise period, time of day and phase within the 5 days (first and last 48 hours), which showed that IDeg dose reductions around regular exercise were not accompanied by large glucose fluctuations. Free plasma insulin levels were similar between 100% IDeg and 75% IDeg, with numerically slightly higher levels while on 100% IDeg. Similarly to the authors of previous studies, we observed a drop in plasma insulin levels during exercise. 6, 30 Most bolus insulins show their peak action~2 hours after injection, followed by a decrease in circulating insulin levels through attenuation of bolus insulin. 31, 32 In the present study, exercise was performed at least 2 hours after bolus insulin injection, which might explain the decrease in plasma insulin levels during exercise, as bolus insulin action mitigates.
While the present study shows that the time spent in euglycaemia during multiple moderate exercise sessions is increased with the 75%
IDeg dosing scheme, we have to clearly acknowledge that a number of findings (eg, time spent in hypoglycaemia, prandial carbohydrate intake) were approaching but not reaching statistical significance and should be interpreted with caution. Larger exercise trials in people with T1D are urgently needed to clarify dose adjustments around exercise sessions of various types and volumes.
Despite the fact that regular IGlar is associated with more hypoglycaemic episodes than basal insulin detemir (IDet; Levemir, Novo Nordisk) during and after exercise, 11 a 20% reduction in both IGlar and IDet protected against hypoglycaemia for 24 hours after evening exercise. 10 The extended duration of action of IDeg could lead to the misinterpretation that patients lose flexibility in dose adjustments around exercise. 5 This might hold true for isolated, unregular exercise bouts, but the present study demonstrates that for participants with T1D performing exercise over 5 consecutive days, IDeg can be used but the dose should be reduced by 25%, as has been observed for other long-acting insulin analogues.
